Skip to main content
. 2024 Jan 18;14(5):727–736. doi: 10.1158/2159-8290.CD-23-1138

Figure 3.

Figure 3. Frequencies of NRASG12C, HRASG12C, and KRASG12C mutations in cancer. A, Percentage of HRASG12C, NRASG12C, and KRASG12C mutations observed in 148,268 cancers from the AACR GENIE database. B, Of all cases with HRAS, NRAS, or KRAS mutations, the percentage with G12C mutations, other mutations of glycine 12 (G12), or other mutations not involving G12 are shown. C, Frequencies of HRASG12C, NRASG12C, and KRASG12C mutations observed in specific cancer types. Actual numbers of cases with each mutation in specific diseases are indicated above each column.

Frequencies of NRASG12C, HRASG12C, and KRASG12C mutations in cancer. A, Percentage of HRASG12C, NRASG12C, and KRASG12C mutations observed in 148,268 cancers from the AACR GENIE database. B, Of all cases with HRAS, NRAS, or KRAS mutations, the percentage with G12C mutations, other mutations of glycine 12 (G12), or other mutations not involving G12 are shown. C, Frequencies of HRASG12C, NRASG12C, and KRASG12C mutations observed in specific cancer types. Actual numbers of cases with each mutation in specific diseases are indicated above each column.